Georgia Regents University

Home » Cancer Center » Clinical Trials » Clinical Trials

Clinical Trials

David Munn, MD and Andrew Mellor, PhD

In the News

New drug starts at GRU Cancer Center

First patient begins treatment in Cancer Center's newest first in human trial for the drug called NLG919.


As an academic medical center, the GRU Cancer Center in Augusta, GA is actively involved in cancer research for cancer patients.

Clinical trials are the last step in a carefully regulated, detailed scientific process that starts in a laboratory in cells or tissue and are then tested in humans—oftentimes years later and always after strenuous review.

Medical studies are supervised by a local physician and look at every stage of disease, from first diagnosis to advanced disease. All are designed to find, diagnose, treat or prevent cancer.

Program Highlights


Current Clinical Trial Studies

Phase I


Cancer Control & Prevention

Bone Marrow Transplant / Hematological Malignancy

Breast Cancer


Genitourinary Oncology

Gynecologic Oncology

Head & Neck

Lung Cancer

Neurological Oncology

Pediatric Oncology


Photo: Cancer Center to lead state’s only minority-focused research programCancer Center to lead state’s only minority-focused research program

The GRU Cancer Center has been awarded a five-year grant from the National Cancer Institute to lead the state’s only cancer research program focused on better access to clinical trials and cancer treatments for minority and underserved patients.

Working in partnership with the Morehouse School of Medicine, University Cancer and Blood Center, and the Jiann-Ping Hsu College of Public Health at Georgia Southern University – the Community Oncology Research Program Minority/Underserved Community Site at GRU Cancer Center will aim to increase awareness of, and participation in, NCI-sponsored clinical trials and cancer care delivery research throughout Georgia, particularly among minority and underserved populations.

As the only site of its kind in Georgia, and one of just 12 selected nationally, the GRU Cancer Center–led consortium will contribute to the design, conduct, and translation of the national NCORP research agenda, particularly studies pertaining to minority and underserved populations. Key stakeholders and community partners will help to set priorities for community-based cancer research and work collectively to address the historic barriers that have stood in the way of minority and underserved patients participating in clinical trials and other important cancer research.

“We are honored to work with our colleagues from around the state to build on more than a decade of experience serving as a Minority-Based CCOP,” said Dr. Samir N. Khleif, Director of the GRU Cancer Center. “And, we appreciate NCI’s confidence in the ability of the GRU Cancer Center and our outstanding NCORP partners to positively impact the tremendous cancer health disparities that exist in Georgia among minorities and medically underserved populations. This grant is in perfect alignment with our shared commitment to serve all Georgians with the best possible cancer care.”

The GRU Cancer Center is a multidisciplinary academic cancer center focused on both research and clinical treatment. Its patient-centered approach to treatment includes first-in-the-nation treatment protocols, an experimental therapeutics program that includes specialized clinics for Phase I trials and immunotherapy, and a variety of ancillary programs – including music therapy and genetic counseling – designed with holistic healing in mind.


Transparent Panel for Emergency Use